Last updated: February 13, 2026
Overview
NDC 16571-0769 is a medication marketed under the drug name "Xyrem" (sodium oxybate). It is primarily prescribed for narcolepsy-related cataplexy and excessive daytime sleepiness. Xyrem is controlled under Schedule III in the U.S., with a high degree of regulation due to its abuse potential.
Market Size and Growth
The pharmaceutical market for narcolepsy treatments, including sodium oxybate, is estimated at $600 million globally in 2023. The U.S. accounts for approximately 80% of this market. The prevalence of narcolepsy is roughly 135 per 100,000 individuals, with an estimated 200,000 Americans affected.
Key Market Drivers:
- Increased diagnosis rates due to better awareness.
- Patent exclusivities extending until 2028, limiting generic competition.
- Growing acceptance of sodium oxybate for narcolepsy and comorbid conditions.
Competitive Landscape
The market includes:
- Parent drug: Xyrem (Jazz Pharmaceuticals), with a monopoly until patent expiry in 2028.
- Emerging alternatives: Solriamfetol (competitive with lower regulatory barriers).
- Generics: Not available due to patent protections until 2028.
Pricing Dynamics
Current Price Point:
- The average wholesale price (AWP) for Xyrem is approximately $80 per 5 mL of the liquid formulation.
- Estimated monthly treatment cost per patient: $4,000–$4,500, assuming average dose and patient usage patterns.
- Out-of-pocket costs vary based on insurance coverage but typically range from $300 to $1,000.
Pricing Compared to Alternatives:
- Solriamfetol (Sunosi): approximately $500-$700/month.
- Sodium oxybate: roughly 6-9 times more expensive, reflective of its controlled substance status and manufacturing costs.
Patent and Regulatory Outlook
Xyrem’s patent protection extends until 2028, with data exclusivity until 2029, delaying generic entry. Any biosimilars or substitutes would likely take another five years post-patent expiry to reach significant market penetration.
Price Projections
| Year |
Estimated Price Range (per month) |
Notes |
| 2023 |
$4,000–$4,500 |
Current market pricing |
| 2024–2026 |
$4,000–$4,200 |
Slight decline possible due to market dynamics |
| 2027 |
$4,000 |
Market stability until patent expiry |
| 2028 |
Sharp decline expected |
Patent expiry, introduction of generics anticipated |
| 2029+ |
$1,000–$2,000 |
Generic uptake, possible biosimilars |
Market Risks and Opportunities
-
Risks:
- Patent cliff in 2028, pending patent litigation or regulatory delays.
- Regulatory changes reducing prescribing restrictions.
- Emergence of new therapies with improved safety profiles.
-
Opportunities:
- Expansion into related indications (e.g., alcohol dependence).
- Development of novel formulations or delivery methods.
- Entry of biosimilars post-patent expiry to reduce prices.
Regulatory and Policy Impact
FDA’s focus on abuse potential has led to stringent use restrictions, potentially impacting market access. Price transparency initiatives may pressure list prices, but monopoly pricing remains dominant due to lack of competition.
Summary
NDC 16571-0769 (Xyrem) maintains a high price point driven by patent exclusivity until 2028. The U.S. market remains dominant, with limited competition. Post-2028, prices are expected to decline significantly with the introduction of generics, but market share for sodium oxybate is likely to decrease unless new formulations or indications emerge.
Key Takeaways
- The current annual treatment cost is approximately $48,000.
- Patent expiry in 2028 is a critical inflection point for price reduction.
- The market is heavily regulated, limiting immediate generic competition.
- Price decline projections post-2028 suggest a roughly 50-75% reduction.
- Opportunities exist in new indications and delivery systems.
FAQs
-
When will generic versions of sodium oxybate likely become available?
- Post-2028, following patent expiry and regulatory approvals.
-
How does the cost of sodium oxybate compare with alternative therapies?
- It is approximately 6-9 times more expensive than drugs like solriamfetol.
-
What factors influence the market size for narcolepsy drugs?
- Diagnosis rates, insurance coverage, and regulatory restrictions.
-
Are biosimilars expected to impact prices before 2028?
- No, biosimilars are unlikely before patent expiration.
-
What policies could accelerate price declines?
- Patent challenges, regulatory changes easing access, or new competing therapies.
References
[1] IMS Health, 2023. Global Pharmaceutical Market Data.
[2] FDA. Sodium oxybate (Xyrem) drug details and regulatory status.
[3] Symphony Health. Current drug pricing and insurance coverage analysis.
[4] National Sleep Foundation. Epidemiology of narcolepsy.
[5] Jazz Pharmaceuticals. Xyrem patent and exclusivity filings.
